FTD Clinical Trial

FTD Clinical Trial Passage Bio is studying a potential new therapy called PBFT02 for the treatment of FTD-GRN. This page provides information about the upliFT-D clinical trial.

Passage Bio is studying a potential new therapy called PBFT02 for the treatment of frontotemporal dementia caused by a GRN mutation (FTD-GRN). Visit FTDclinicaltrial.com to learn more about upliFT-D. GLOBAL-FTD-019-05242024

Interested in learning more about a potential new therapy called PBFT02 for the treatment of frontotemporal dementia cau...
03/28/2023

Interested in learning more about a potential new therapy called PBFT02 for the treatment of frontotemporal dementia caused by a GRN mutation?

We are here to help, and we're happy to answer any questions you may have about FTD, the treatment we are studying, and the clinical trial: https://passagebioclinicaltrials.com/Frontotemporal-Dementia/

Address

Philadelphia, PA

Website

Alerts

Be the first to know and let us send you an email when FTD Clinical Trial posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category